Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. Podcast with prof. Grant Stewart about the NAXIVA trial: a phase II study of neoadjuvant axitinib for
    reducing extent of venous tumour thrombus in clear cell renal cell carcinoma

2. Intensifying the radiotherapy dose in prostate cancer patients with PSA recurrence after prostatectomy
    does not increase the biochemical recurrence-free survival

3. Belzutifan plus cabozantinib displays clinical efficacy in treatment-exposed clear cell renal cell carcinoma

4. Docetaxel in combination with nivolumab in metastatic castration-resistant prostate cancer: Final analysis
    of cohort B of the phase II CheckMate 9KD trial

5. Gemcitabine, split-dose cisplatin and pembrolizumab as neoadjuvant therapy before a radical cystectomy
    in muscle-invasive bladder cancer patients